Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk’s Wegovy in a study.
Eli Lilly’s Zepbound beats Wegovy in head-to-head weight loss trial
Tum Rakshak Kahu Ko Darna
Tum Rakshak Kahu Ko Darna
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk’s Wegovy in a study.
